39 related articles for article (PubMed ID: 35652795)
1. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
2. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
3.
Fei F; Caporale C; Chang L; Fortini BK; Ali H; Bell D; Stein A; Marcucci G; Telatar M; Afkhami M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791222
[No Abstract] [Full Text] [Related]
4. Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.
Sheikhi M; Rostami M; Ferns G; Ayatollahi H; Siyadat P; Ayatollahi Y; Khoshnegah Z
Caspian J Intern Med; 2024; 15(2):202-214. PubMed ID: 38807730
[TBL] [Abstract][Full Text] [Related]
5. A Case of Chronic Eosinophilic Leukemia with CSF3R-Mutant Clone and Transformed to Secondary Acute Myeloid Leukemia.
Wu Y; Yang X
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623671
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.
Segura-Díaz A; Stuckey R; Florido Y; Sobas M; Álvarez-Larrán A; Ferrer-Marín F; Pérez-Encinas M; Carreño-Tarragona G; Fox ML; Tazón Vega B; Cuevas B; López Rodríguez JF; Sánchez-Farías N; González-Martín JM; Gómez-Casares MT; Bilbao-Sieyro C;
Thromb Haemost; 2024 Jan; ():. PubMed ID: 38190984
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes.
Paudel BB; Tan SF; Fox TE; Ung J; Golla U; Shaw JJP; Dunton W; Lee I; Fares WA; Patel S; Sharma A; Viny AD; Barth BM; Tallman MS; Cabot M; Garrett-Bakelman FE; Levine RL; Kester M; Feith DJ; Claxton D; Janes KA; Loughran TP
Blood Adv; 2024 Mar; 8(5):1137-1142. PubMed ID: 38170742
[No Abstract] [Full Text] [Related]
8. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G; Rausch CR; Sasaki K; Hammond D; Morita K; Takahashi K; Tang G; Kanagal-Shamanna R; Bhalla K; Dinardo CD; Borthakur G; Pemmaraju N; Shpall EJ; Alousi A; Daver NG; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM; Kadia TM
Haematologica; 2023 Sep; 108(9):2331-2342. PubMed ID: 36951163
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N; Jahn E; Saadati M; Bullinger L; Larson RA; Ottone T; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Ehninger G; Heuser M; Ganser A; Pallaud C; Gathmann I; Krzykalla J; Benner A; Bloomfield CD; Thiede C; Stone RM; Döhner H; Döhner K
Leukemia; 2022 Sep; 36(9):2218-2227. PubMed ID: 35922444
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognostic implications of RAS mutations in newly diagnosed acute myeloid leukemia with normal karyotype based on next-generation sequencing analysis].
Liang HZ; Ma YP; Yang LH; Guo QH; Wang SF; Li C
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):762-766. PubMed ID: 38049321
[No Abstract] [Full Text] [Related]
12. The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
Chen X; Tian C; Hao Z; Pan L; Hong M; Wei W; Muyey DM; Wang H; Chen X
Cancer Med; 2023 May; 12(9):10340-10350. PubMed ID: 36912186
[TBL] [Abstract][Full Text] [Related]
13. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
[TBL] [Abstract][Full Text] [Related]
15. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H; Podoltsev NA; Siddon AJ
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
[TBL] [Abstract][Full Text] [Related]
16. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
[TBL] [Abstract][Full Text] [Related]
17. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
